# Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

> **NCT02751931** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 91 (actual)

## Conditions studied

- Neurogenic Detrusor Overactivity

## Interventions

- **DRUG:** Mirabegron

## Key facts

- **NCT ID:** NCT02751931
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-17
- **Primary completion:** 2018-11-05
- **Final completion:** 2019-05-06
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02751931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02751931, "Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02751931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*